AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-21. (canceled)

22. (currently amended) A method for locally treating buccopharyngeal ailments in a subject, comprising:

~~by local permucosal diffusion comprising administering the tablet according to claim 9 to a subject in need thereof~~

providing a composition comprising a non-steroidal anti-inflammatory drug (NSAID) in a water-soluble amino acid salt form;

orally and locally administering the composition to the subject; and

allowing the composition to solubilize in the buccopharyngeal cavity of the subject, the composition being solubilized by the saliva of the subject, the amino acid dissociating from the NSAID thereby imparting a lipophilic property to the NSAID, and said lipophilic NSAID actively diffusing through mucous tissues in the buccopharyngeal cavity of the subject without recrystallizing.

23-24. (canceled)

25. (new) The method of claim 22, wherein the composition comprises less than 2.5 wt% of NSAID.

26. (new) The method of claim 22, wherein when the composition is solubilized by the saliva, a bioadhesive film is created on the mucous membranes slowing down the dissolution and the release of the NSAID in the saliva and keeping the composition in place locally so as to limit loss of the composition by the act of swallowing.

27. (new) The method of claim 22, wherein the amino acid is lysine.

28. (new) The method of claim 22, wherein the NSAID is ibuprofen, ketoprofen, or a combination thereof.

29. (new) The method of claim 22, wherein the NSAID is ibuprofen.

30. (new) The method of claim 22, wherein the NSAID in a water-soluble amino acid salt form is ibuprofen lysinate or ketoprofen lysinate.

31. (new) The method of claim 22, wherein the composition is in a tablet form.

32. (new) The method of claim 22, wherein the composition comprises a substrate that makes possible a slow permucosal diffusion that is uniform and localized to the buccopharyngeal cavity.

33. (new) The method of claim 32, wherein the substrate comprises a carbohydrate.

34. (new) The method of claim 22, wherein the composition comprises a polymer agent that is selected from the group consisting of a cellulose derivative, a gum, alginic acid and derivatives, carboxy-vinyl polymer, carbomer, macrogol, polyethylene glycol, gelatin, povidone, and pectin.

35. (new) The method of claim 22, wherein the composition is in a tablet form and has the following formulation:

ibuprofen lysinate	25 mg
magnesium stearate	10 mg
talc	50 mg
aspartame	15 mg

hydroxy-propyl-methyl	
cellulose	70 mg
Arome	20 mg
sorbitol	810 mg .

36. (new) The method of claim 22, wherein the composition is in a tablet form and has the following formulation:

ketoprofen lysinate	5 mg
magnesium stearate	10 mg
talc	50 mg
aspartame	15 mg
hydroxy-propyl-methyl	
cellulose	70 mg
Arome	20 mg
sorbitol	830 mg .